Mark Sheptoff Financial Planning, LLC Exelixis, Inc. Transaction History

Mark Sheptoff Financial Planning, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$16.3 - $21.14 $17,930 - $23,254	-1,100 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$16.46 - $27.42 $4,938 - $8,226	300 Added 37.5%	1,100 $26,000
Q4 2019 Feb 10, 2020	BUY	$15.15 - $18.89 $3,030 - $3,778	200 Added 33.33%	800 $14,000
Q3 2019 Nov 12, 2019	SELL	$17.68 - $22.65 $5,304 - $6,795	-300 Reduced 33.33%	600 $11,000
Q1 2019 May 10, 2019	BUY	$19.6 - $24.76 $17,640 - $22,284	900 New	900 $21,000
Q4 2018 Feb 11, 2019	SELL	$13.65 - $21.8 $17,745 - $28,340	-1,300 Closed	0 $0
Q1 2018 May 08, 2018	SELL	$22.15 - $31.89 $56,482 - $81,319	-2,550 Reduced 66.23%	1,300 $29,000
Q4 2017 Feb 09, 2018	SELL	$24.23 - $30.93 $26,653 - $34,023	-1,100 Reduced 22.22%	3,850 $117,000
Q3 2017 Nov 09, 2017	BUY	$23.35 - $29.24 $115,582 - $144,738	4,950	4,950 $120,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Mark Sheptoff Financial Planning, LLC, based on Form 13F filings with the SEC.

Stay updated on Mark Sheptoff Financial Planning, LLC with notifications on news.